EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Characterising the Economic Burden of Functional Dyspepsia: A Cost‐of‐Illness Study of Direct and Indirect Costs

Daan H C A Bosch, Brigitte A B Essers, Abraham B Beckers, Johanna T W Snijkers iD, Bjorn Winkens, Ad A M Masclee, Daniel Keszthelyi iD

United European Gastroenterology Journal · 2026

DOI: 10.1002/ueg2.70257 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift United European Gastroenterology Journal, 2026. Verfasst von Daan H C A Bosch und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands. Hauptthemen laut MEDLINE: Cost of Illness, Dyspepsia, Health Care Costs. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Functional dyspepsia (FD) is a prevalent disorder of gut‐brain interaction (DGBI) and is associated with substantial impact on health care utilisation. However, analyses examining patient‐specific characteristics that contribute to this burden remain limited. This study assessed the economic burden of patients with FD and examined patient‐specific characteristics related to costs.

Methods

Patients who had been recruited for a randomised controlled trial completed several questionnaires. Health care utilisation and productivity losses were measured using the iMTA Medical Consumption Questionnaire and Productivity Cost Questionnaire. Participants also completed the EuroQol 5‐Dimension 5‐Level, Nepean Dyspepsia Index, Generalised Anxiety Disorder‐7, and Patient Health Questionnaire‐9. Non‐parametric bootstrapping was applied to calculate the mean annual costs. Multivariable linear regression was used to identify patient‐specific characteristics associated with costs.

Results

Data were obtained from 73 participants (median age 39 years; 75% female). Mean annual total costs accounted for €12,192 (2.5th to 97.5th percentiles, €1125 to €36,369), of which €10,240 (2.5th to 97.5th percentiles, €0 to €34,771) were indirect costs. Higher disease‐specific quality of life (QoL) was associated with lower annual total costs (regression slope = −€4726 per 0.1‐point increase in QoL; 95% CI, −€7636 to −€1815; p = 0.002), while symptom severity, generic health‐related QoL or scores for anxiety or depression were not significantly associated.

Conclusion

Patients with poorer disease‐specific QoL, but not necessarily those with more severe symptoms or higher scores for anxiety and depression, are particularly likely to incur higher annual costs. Understanding the nature of costs and associated patient characteristics is essential for enabling more targeted strategies. Trial Registration The TENDER trial was registered on Clinicaltrials.gov under NCT03652571 on August 17, 2018.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cost of IllnessDyspepsiaHealth Care CostsAdultFemaleHumansMaleMiddle AgedQuality of LifeSeverity of Illness IndexSurveys and Questionnaires

Stichwörter der Autor:innen

cost‐of‐illnessdisorder of gut‐brain interactioneconomic burdenfunctional dyspepsiaquality of life

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, the Netherlands.
  • KEMTA Department of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre+, Maastricht, the Netherlands.
  • CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands.
  • Department of Methodology and Statistics, Maastricht University, Maastricht, the Netherlands.

ORCID-Profile: Johanna T W Snijkers, Daniel Keszthelyi

Förderung

  • ZonMw

Zitieren

APA

Bosch, D. H. C. A., Essers, B. A. B., Beckers, A. B., Snijkers, J. T. W., Winkens, B., Masclee, A. A. M., & Keszthelyi, D. (2026). Characterising the Economic Burden of Functional Dyspepsia: A Cost‐of‐Illness Study of Direct and Indirect Costs. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.70257

Vancouver

Bosch DHCA, Essers BAB, Beckers AB, Snijkers JTW, Winkens B, Masclee AAM, et al. Characterising the Economic Burden of Functional Dyspepsia: A Cost‐of‐Illness Study of Direct and Indirect Costs. United European Gastroenterology Journal. 2026. doi:10.1002/ueg2.70257

BibTeX
@article{Bosch2026,
  author = {Bosch, Daan H C A and Essers, Brigitte A B and Beckers, Abraham B and Snijkers, Johanna T W and Winkens, Bjorn and Masclee, Ad A M and Keszthelyi, Daniel},
  title = {Characterising the Economic Burden of Functional Dyspepsia: A Cost‐of‐Illness Study of Direct and Indirect Costs},
  journal = {United European Gastroenterology Journal},
  year = {2026},
  doi = {10.1002/ueg2.70257}
}
Kostenlos starten →